Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

To join this study, you need to be between 55 and 84 years old. You must have a clear diagnosis of either Parkinson's disease with dementia or probable dementia with Lewy bodies. Additionally, you need to be experiencing psychosis related to your dementia.

There are also some reasons why you might not be able to join. For example, if your psychotic symptoms are primarily due to something else, like delirium, substance use, or a different mental health condition, this study might not be right for you. If you have serious or unstable health conditions affecting your heart, lungs, kidneys, liver, or other major body systems, or if you've recently had a stroke or significant head injury, you would likely not be able to take part.

Finally, if you are currently receiving hospice care, are bedridden, or have conditions that would make it difficult to follow the study procedures, you wouldn't be eligible. It's important that your general health is stable enough to safely participate.

If you decide to take part, you'll be involved in this study for about 6 weeks. Before starting, there will be a 'screening visit' to check if you meet all the requirements. If you do, you'll then have a 'baseline visit' where various assessments will be done.

Throughout the study, you'll be given either the new study drug, ACP-204, or an inactive dummy pill (placebo). Neither you nor your study doctor will know which one you are receiving. You will have regular visits to the study clinic where the research team will monitor your health, check for any changes in your symptoms, and assess how well you are coping. These visits will likely include physical examinations, blood tests, and questionnaires to track your symptoms and overall well-being. It's important to attend all scheduled visits and follow the study instructions carefully. After the 6-week treatment period, there will be a final follow-up to ensure your safety.